Cargando…
Type 1 diabetes and cardiovascular disease
The presence of cardiovascular disease (CVD) in Type 1 diabetes largely impairs life expectancy. Hyperglycemia leading to an increase in oxidative stress is considered to be the key pathophysiological factor of both micro- and macrovascular complications. In Type 1 diabetes, the presence of coronary...
Autores principales: | Schnell, Oliver, Cappuccio, Francesco, Genovese, Stefano, Standl, Eberhard, Valensi, Paul, Ceriello, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816572/ https://www.ncbi.nlm.nih.gov/pubmed/24165454 http://dx.doi.org/10.1186/1475-2840-12-156 |
Ejemplares similares
-
Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020) -
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016) -
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2018) -
Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017) -
Correction to: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)